Pharma-informatics system

Details for Australian Patent Application No. 2006239221 (hide)

Owner Proteus Biomedical, Inc.

Inventors Pikelny, Aleksandr; Robertson, Timothy; Thompson, Andrew; Zdeblick, Mark

Agent Pizzeys

Pub. Number AU-B-2006239221

PCT Pub. Number WO2006/116718

Priority 60/694,078 24.06.05 US; 60/676,145 28.04.05 US; 60/790,335 07.04.06 US; 60/713,680 01.09.05 US

Filing date 28 April 2006

Wipo publication date 2 November 2006

Acceptance publication date 15 March 2012

International Classifications

A61B 5/07 (2006.01) Measuring for diagnostic purposes - Endoradiosondes

A61K 9/48 (2006.01) Medicinal preparations characterised by special physical form - Preparations in capsules, e.g. of gelatin, of chocolate

Event Publications

29 November 2007 PCT application entered the National Phase

  PCT publication WO2006/116718 Priority application(s): WO2006/116718

15 March 2012 Application Accepted

  Published as AU-B-2006239221

26 April 2012 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 20 Mar 2012. Address for service in Australia - Pizzeys Level 2, Woden Plaza Offices Woden Town Square Woden Canberra ACT 2606

23 August 2012 Standard Patent Sealed

25 October 2012 Application for Amendment

  The nature of the amendment is: Amend the Patentee to read Proteus Digital Health, Inc. . Address for service in Australia - Pizzeys Level 2, Woden Plaza Offices Woden Town Square Woden Canberra ACT 2606

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006239222-Peelable atraumatic tip and body for a catheter or sheath

2006239219-Materials and methods for enhanced degradation of mutant proteins associated with human disease